Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 36Terminated 6No longer available 4Recruiting 3Active not recruiting 3Withdrawn 2Suspended 1

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × dabrafenib × Clear all
NCT02447939 2018-09-14

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

GlaxoSmithKline

Phase 1 Withdrawn
Dermatologic

Melanoma

NCT02672358 2018-08-10

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Novartis

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡